Abstract
Aim:
To determine the inhibitory potential of 2 new fluoroquinolones, caderofloxacin and antofloxacin, together with 4 marketed fluoroquinolones, moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin, on the activity of cytochrome P450 isoforms 1A2 (CYP1A2) and 2C9 (CYP2C9).
Methods:
Probe substrates, phenacetin (CYP1A2), and tolbutamide (CYP2C9) were incubated with human liver microsomes and the metabolites were analyzed by liquid chromatography/mass spectrometry using electrospray ionization in positive or negative mode. Glipizide was used as the internal standard in both modes. The inhibitory potential of fluoroquinolones on CYP1A2 and CYP2C9 was investigated.
Results:
The IC50 values (μmol/L) determined with the cocktail were in agreement with individual probe substrates (α-naphthoflavone: 0.27 vs 0.26; sulfaphenazole: 0.49 vs 0.37). Ciprofloxacin showed weak inhibition on both the activity of CYP1A2 (IC50 135 μmol/L) and CYP2C9 (IC50 180 μmol/L), whereas levofloxacin inhibited only CYP2C9 (IC50 210 μmol/L). Caderofloxacin, antofloxacin, moxifloxacin, and gatifloxacin showed little or no inhibition on the activity of CYP1A2 or CYP2C9 when tested at comparable concentrations (0–200 mg/L).
Conclusion:
Caderofloxacin, antofloxacin, moxifloxacin, and gatifloxacin are negligible inhibitors to CYP1A2 and CYP2C9. The in vitro system can be used as a high-throughput model to screen similar compounds for the early identification of drug-drug interaction potential.
Similar content being viewed by others
Article PDF
References
Hooper DC, Wolfson JS . Fluoroquinolone antimicrobial agents. N Engl J Med 1991; 324: 384–94.
Biedenbach DJ, Sutton LD, Jones RN . Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother 1995; 39: 2325–30.
Masuda N, Takahashi Y, Otsuki M, Ibuki E, Miyoshi H, Nishino T . In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Antimicrob Agents Chemother 1996; 40: 1201–7.
Beckmann, Elsässer W, Gundert-Remy U, Hertrampf R . Enoxacin — a potent inhibitor of theophylline metabolism. Eur J Clin Pharmacol 1987; 33: 227–30.
Maesen FP, Teengs JP, Baur C, Davies BI . Quinolones and raised plasma concentrations of theophylline. Lancet 1984; 8401: 530–5.
Raoof S, Wollschlager C, Khan F . Serum theophylline levels are increased by ciprofloxacin (BAY 9687), a new quinolone antibiotic. Chest 1985; 99 Suppl: 32.
Wijnands WJ, Van Herwaarden CL, Vree TB . Enoxacin raises plasma theophylline concentrations. Lancet 1984; 8394: 108–9.
Wijnands WJ, Vree TB . Interaction between the fluoroquinolones and the bronchodilator theophylline. J Antimicrob Chemother 1988; 22 Suppl C: 109–14.
Ellis RJ, Mayo MS, Bodensteiner DM . Ciprofloxacin-warfarin coagulopathy: a case series. Am J Hematol 2000; 63: 28–31.
Ravnan SL, Locke C . Levofloxacin and warfarin interaction. Pharmacotherapy 2001; 21: 884–5.
Gheno G, Cinetto L . Levofloxacin–warfarin interaction (letter). Eur J Clin Pharmacol 2001; 57: 427–8.
Jones CB, Fugate SE . Levofloxacin and warfarin interaction. Ann Pharmacother 2002; 36: 1554–7.
Ansede JH, Thakker DR . High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism. J Pharm Sci 2004; 93: 239–55.
Lake B . Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism. In: Snell K, Mullock B, editors. Biochemical toxicology: a practical approach. Washington: IRL-Press; 1987. p 183–9.
Bradford MM . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.
He F, Bi HC, Xie ZY, Zuo Z, Li JK, Li X, et al. Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 2007; 21: 635–43.
Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE . A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 2001; 29: 23–9.
Testino SA, Patony G . High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2003; 30: 1459–67.
Yuan R, Madani S, Wei XX, Reynolds K, Huang SM . Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 2002; 30: 1311–9.
Shader RI, Granda BW, von Moltke LL, Giancarlo GM, Greenblatt DJ . Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. Biopharm Drug Dispos 1999; 20: 385–8.
Yin H, Racha J, Li SY, Olejnik N, Satoh H, Moore D . Automated high throughput human CYP isoform activity assay using SPE LC/MS method: application in CYP inhibition evaluation. Xenobiotica 2000; 30: 141–54.
Bu HZ, Knuth K, Magis L, Teitelbaum P . High throughput cytochrome P450 (CYP) inhibition screening via a cassette probe dosing strategy. Validation of a direct injection/online guard cartridge extraction tandem mass spectrometry method for CYP1A2 inhibition assessment. Eur J Pharm Sci 2001; 12: 447–52.
Walsky RL, Obach RS . Validated assays for human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 647–60.
Pea F, Pavan F, Di Qual E, Brollo L, Nascimben E, Baldassarre M, et al. Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia. J Chemother 2003; 15: 563–7.
Wagenlehner FM, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Dalhoff A, et al. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Intern J Antimicrob Agents 2006; 27: 7–14.
Fish DN . Evaluation of gatifloxacin pharmacokinetics and pharmacodynamics in severely ill adults in a medical Intensive Care Unit. Intern J Antimicrob Agents 2007; 29: 715–23.
Wagenlehner FM, Kees F, Weidner W, Wagenlehner C, Naber KG . Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int J Antimicrob Agents 2008; 31: 21–6.
Liu L, Pang X, Zhang D, Xu X, Liu H, Liang Y, et al. Determination of caderofloxacin lactate in rat plasma by high-performance liquid chromatography-mass spectrometry and its application in rat pharmacokinetic studies. J Pharm Biomed Anal 2007; 45: 799–803.
Department of Health and Human Services, Food and Drug Administration (US). Guidance for industry: bioanalytical method validation. Beltsville, MD: Department of Health and Human Services, Food and Drug Administration; 2001.
Chauret N, Gauthier A, Griffith DA . Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos 1998; 26: 1–4.
Hickman D, Wang JP, Wang Y, Unadkat JD . Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998; 26: 207–15.
Busby WF, Ackermann JM, Crespi CL . Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450. Drug Metab Dispo 1999; 27: 246–9.
Kim MJ, Kim H, Cha IJ, Park JS, Shon JH, Liu KH, et al. High-throughput screening of inhibitory potential of nine cytochrome p450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrum 2005; 19: 2651–8.
Hu JH, Xie L, Liu XD . Determination of antofloxacin in rat plasma and bile by HPLC and study of its pharmacokinetics. J China Pharm Univ 2006; 37: 153–6 (in Chinese).
Xiao YH, Lu Y, Kang ZS, Zhang M, Liu Y, Zhang M, et al. Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquino-lone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 2008; 29: 167–72.
White RE . High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 2000; 40: 133–57.
Stass H, Kubitza D . Profile of moxifloxacin drug interactions. Clin Infect Dis 2001; 32 Suppl 1: S47–50.
Niki Y, Hashiguchi K, Miyashita N, Nakajima M, Matsushima T . Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline. J Infect Chemother 1999; 5: 156–62.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, L., Wei, Mj., Zhao, Cy. et al. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin 29, 1507–1514 (2008). https://doi.org/10.1111/j.1745-7254.2008.00908.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00908.x
Keywords
This article is cited by
-
Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats
Acta Pharmacologica Sinica (2016)
-
Modulation of pharmacokinetics of theophylline by antofloxacin, a novel 8-amino-fluoroquinolone, in humans
Acta Pharmacologica Sinica (2011)